Clnp.Wa
CLNP.WA operates in the pharmaceuticals industry, focusing on the development, production, and distribution of pharmaceutical products.
Business. CLNP.WA operates in the pharmaceuticals industry, focusing on the development, production, and distribution of pharmaceutical products.
Analyst recommendations
5 analysts · consensus HoldAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
CLNP.WA operates in the pharmaceuticals industry, focusing on the development, production, and distribution of pharmaceutical products.
The company's capital structure is characterized by a low debt-to-equity ratio of 0.05, indicating a conservative leverage profile. However, the company reported negative free cash flow of -63.395 million PLN, which is a concern for liquidity and reinvestment capacity. The current ratio of 1.68 suggests the company has sufficient short-term assets to cover its short-term liabilities, but the negative operating income of -58.686 million PLN and net loss of -78.430 million PLN indicate operational challenges.
Profitability metrics are significantly below industry norms, with a return on equity of -21.53% and a return on assets of -17.24%. These figures suggest the company is not generating returns that meet the cost of capital, which is a red flag for investors. The gross profit margin of 72.2% is relatively high, but the operating margin is negative, indicating high operating expenses or low pricing power.
The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification increases exposure to regional economic and regulatory risks. The absence of segment or geographic breakdown limits the ability to assess the company's exposure to different markets or product lines.
The company's growth trajectory is uncertain, with no clear revenue growth or decline indicated in the available data. The negative operating income and net loss suggest a need for operational improvements or cost reductions to achieve profitability. The capital expenditure of -32.871 million PLN indicates ongoing investment, but the negative free cash flow suggests these investments are not yet generating positive returns.
Risk factors include the company's negative net income and operating income, which could lead to liquidity constraints if not addressed. The low dilution risk is a positive, but the company's negative free cash flow and high operating expenses are potential red flags for future financial stability. No immediate filing-based liquidity or dilution flags were detected, but the company's financial performance suggests a need for close monitoring.
Recent events include the publication of the latest financial data, which shows a net loss and negative operating income. No significant filings or transcripts were disclosed in the available data, but the company's financial performance indicates a need for strategic adjustments to improve profitability and cash flow.
- CLNP.WA has a conservative capital structure with a low debt-to-equity ratio of 0.05.
- The company is currently unprofitable, with a return on equity of -21.53% and a return on assets of -17.24%.
- Revenue concentration in a single segment increases exposure to market-specific risks.
- Negative free cash flow of -63.395 million PLN indicates liquidity and reinvestment challenges.
- Analysts have a mixed outlook, with a mean price target of 18.57 PLN and a mean recommendation of 3.20.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- CLNP.WA Market data — financials · 2026-05-27
- Celon Pharma SA Market data — analyst estimates · 2026-05-27
Ownership & reference
Leadership
- Robert Stanislaw RzeminskiChairman of the Supervisory Board